Lyvgen Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 8

Lyvgen General Information

Description

Developer of immunotherapy candidates designed to treat cancer patients. The company utilises a functional platform to create agonist antibodies with tumour-localised immunostimulatory activities by balancing multiple functions of candidate antibodies, providing oncology therapeutics to improve patient outcomes through tumour-targeted immune activation.

Contact Information

Website
www.lyvgen.cn
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Suite 317, Building 1
  • 351 Guoshoujing Road
  • Shanghai
  • China
+86 021
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • Suite 317, Building 1
  • 351 Guoshoujing Road
  • Shanghai
  • China
+86 021

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Lyvgen Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Secondary Transaction - Private 30-Jul-2026 Completed Generating Revenue
4. Later Stage VC (Series C) 23-Feb-2021 Completed Generating Revenue
3. Early Stage VC (Series B1) 01-Dec-2019 Completed Generating Revenue
2. Early Stage VC (Series B) 01-Jun-2018 $30M $35M Completed Generating Revenue
1. Early Stage VC (Series A) 01-Jan-2017 $5M $5M Completed Generating Revenue
To view Lyvgen’s complete valuation and funding history, request access »

Lyvgen Patents

Lyvgen Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-10913797-B2 Anti-pd-1 antibodies and therapeutic uses thereof Active 18-Nov-2015
US-20180346569-A1 Anti-pd-1 antibodies and therapeutic uses thereof Active 18-Nov-2015

Lyvgen Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds
120 Capital Venture Capital Minority
Chengwei Capital Venture Capital Minority
IDG Capital Venture Capital Minority
Shanghai Free Trade Zone Equity Fund Venture Capital Minority
Shenzhen GTJA Investment Group Venture Capital Minority
You’re viewing 5 of 8 investors. Get the full list »

Lyvgen FAQs

  • When was Lyvgen founded?

    Lyvgen was founded in 2016.

  • Where is Lyvgen headquartered?

    Lyvgen is headquartered in Shanghai, China.

  • What industry is Lyvgen in?

    Lyvgen’s primary industry is Drug Discovery.

  • Is Lyvgen a private or public company?

    Lyvgen is a Private company.

  • What is Lyvgen’s current revenue?

    The current revenue for Lyvgen is .

  • How much funding has Lyvgen raised over time?

    Lyvgen has raised $75M.

  • Who are Lyvgen’s investors?

    120 Capital, Chengwei Capital, IDG Capital, Shanghai Free Trade Zone Equity Fund, and Shenzhen GTJA Investment Group are 5 of 8 investors who have invested in Lyvgen.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process